- Home
- CRON vs GLUE Comparison
CRON vs GLUE Comparison
Compare CRON & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRON | GLUE |
|---|---|---|
| Founded | N/A | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 976.4M | 1.1B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRON | GLUE |
|---|---|---|
| Price | $2.80 | $23.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | 1.3M | ★ 2.6M |
| Earning Date | 02-26-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.09 | ★ 0.25 |
| Revenue | $132,357,000.00 | ★ $181,538,000.00 |
| Revenue This Year | $17.63 | $84.02 |
| Revenue Next Year | $30.76 | N/A |
| P/E Ratio | ★ $29.50 | $90.48 |
| Revenue Growth | 19.00 | ★ 1112.27 |
| 52 Week Low | $1.60 | $3.50 |
| 52 Week High | $3.43 | $25.77 |
Technical Indicators
Market Signals| Indicator | CRON | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 57.91 | 60.67 |
| Support Level | $2.50 | $23.01 |
| Resistance Level | $2.80 | $25.35 |
| Average True Range (ATR) | 0.09 | 1.77 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 86.36 | 75.83 |
Price Performance
Historical ComparisonAbout CRON Cronos Group Inc.
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.